215 related articles for article (PubMed ID: 23380248)
1. Novel pharmacological strategies to treat cystic fibrosis.
Hanrahan JW; Sampson HM; Thomas DY
Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
[TBL] [Abstract][Full Text] [Related]
2. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
Birault V; Solari R; Hanrahan J; Thomas DY
Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
[TBL] [Abstract][Full Text] [Related]
3. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
[No Abstract] [Full Text] [Related]
4. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy.
Kerem E
Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796
[TBL] [Abstract][Full Text] [Related]
5. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR.
Sampson HM; Robert R; Liao J; Matthes E; Carlile GW; Hanrahan JW; Thomas DY
Chem Biol; 2011 Feb; 18(2):231-42. PubMed ID: 21338920
[TBL] [Abstract][Full Text] [Related]
6. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
Lukacs GL; Verkman AS
Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
[TBL] [Abstract][Full Text] [Related]
7. Correctors promote folding of the CFTR in the endoplasmic reticulum.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2008 Jul; 413(1):29-36. PubMed ID: 18361776
[TBL] [Abstract][Full Text] [Related]
8. Cytoskeleton and CFTR.
Edelman A
Int J Biochem Cell Biol; 2014 Jul; 52():68-72. PubMed ID: 24685681
[TBL] [Abstract][Full Text] [Related]
9. Dynasore inhibits removal of wild-type and DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) from the plasma membrane.
Young A; Gentzsch M; Abban CY; Jia Y; Meneses PI; Bridges RJ; Bradbury NA
Biochem J; 2009 Jul; 421(3):377-85. PubMed ID: 19442237
[TBL] [Abstract][Full Text] [Related]
10. An overview on chemical structures as ΔF508-CFTR correctors.
Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
[TBL] [Abstract][Full Text] [Related]
11. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy.
Kim Chiaw P; Eckford PD; Bear CE
Essays Biochem; 2011 Sep; 50(1):233-48. PubMed ID: 21967060
[TBL] [Abstract][Full Text] [Related]
12. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
Amaral MD
Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
[TBL] [Abstract][Full Text] [Related]
13. Novel Hits in the Correction of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis.
Pesci E; Bettinetti L; Fanti P; Galietta LJ; La Rosa S; Magnoni L; Pedemonte N; Sardone GL; Maccari L
J Med Chem; 2015 Dec; 58(24):9697-711. PubMed ID: 26561003
[TBL] [Abstract][Full Text] [Related]
14. A chemical corrector modifies the channel function of F508del-CFTR.
Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
[TBL] [Abstract][Full Text] [Related]
15. Repairing the basic defect in cystic fibrosis - one approach is not enough.
Farinha CM; Matos P
FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
[TBL] [Abstract][Full Text] [Related]
16. Rescue of functional CFTR channels in cystic fibrosis: a dramatic multivalent effect using iminosugar cluster-based correctors.
Compain P; Decroocq C; Joosten A; de Sousa J; Rodríguez-Lucena D; Butters TD; Bertrand J; Clément R; Boinot C; Becq F; Norez C
Chembiochem; 2013 Oct; 14(15):2050-8. PubMed ID: 24038832
[TBL] [Abstract][Full Text] [Related]
17. RNF5, DAB2 and Friends: Novel Drug Targets for Cystic Fibrosis.
Sondo E; Pesce E; Tomati V; Marini M; Pedemonte N
Curr Pharm Des; 2017; 23(1):176-186. PubMed ID: 27719636
[TBL] [Abstract][Full Text] [Related]
18. Can correcting the ΔF508-CFTR proteostasis-defect rescue CF lung disease?
Valle CW; Vij N
Curr Mol Med; 2012 Aug; 12(7):860-71. PubMed ID: 22697346
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis.
Dormer RL; Harris CM; Clark Z; Pereira MM; Doull IJ; Norez C; Becq F; McPherson MA
Thorax; 2005 Jan; 60(1):55-9. PubMed ID: 15618584
[TBL] [Abstract][Full Text] [Related]
20. New horizons in the treatment of cystic fibrosis.
Cuthbert AW
Br J Pharmacol; 2011 May; 163(1):173-83. PubMed ID: 21108631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
